What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?   

This is an important question. Benralizumab has recently been shown to have similar efficacy to mepolizumab with a suggestion of a greater number of patients being able to fully discontinue steroids when treated with benralizumab as compared to mepolizumab. On the basis of this study I would use ben...

Guidelines for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) are based on limited data from clinical trials or even protocol-based cohorts. However, there are several ongoing and planned randomized controlled trials that will likely help inform new approaches to treating this...